:: Library Catalog

Image de couverture de livre

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Andrew Hall, Duncan Wilson, Stuart Barber, Sarah R. Brown
Format:	Artículo Open Access
Publié:	Wiley 2026
Sujets:	Statistics in Medicine
Accès en ligne:	https://onlinelibrary.wiley.com/doi/10.1002/sim.70547
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Defining Utility as a Measure of Preference Under Uncertainty in Phase I-II Oncology Dose Finding Trials
par: Hall, Andrew, et autres
Publié: (2025)

Dose Individualization for Phase I Cancer Trials With Broadened Eligibility
par: Rebecca B. Silva, et autres
Publié: (2024)

A Generalized Phase I/II Dose Optimization Trial Design With Multi‐Categorical and Multi‐Graded Outcomes
par: Yichen Yan, et autres
Publié: (2025)

Accounting for Carryover Toxicity in Phase I Clinical Trials with Intra‐Patient Dose Escalation
par: Chloe E. Falke, et autres
Publié: (2025)

On Inclusion of Covariates in Model Based Dose Finding Clinical Trial Designs
par: Adrien Ollier, et autres
Publié: (2025)

Bayesian Safety and Futility Monitoring in Phase II Trials Using One Utility‐Based Rule
par: Juhee Lee, et autres
Publié: (2024)

Sample Size Calculation in Dose Optimization Trials Using the Margin of Practical Non‐Inferiority
par: Hakim‐Moulay Dehbi, et autres
Publié: (2025)

RMST for Interval‐Censored Data in Oncology Clinical Trials
par: Xiyuan Gao, et autres
Publié: (2025)

Testing for Similarity of Dose Response in Multiregional Clinical Trials
par: Holger Dette, et autres
Publié: (2025)

Safety‐Driven Response Adaptive Randomization: An Application in Noninferiority Oncology Trials
par: Maria Vittoria Chiaruttini, et autres
Publié: (2026)

Bayesian Ordered Lattice Design for Phase I Clinical Trials
par: Gi‐Ming Wang, et autres
Publié: (2026)

A Biomarker‐Based Dose–Schedule Optimization Design for Immunotherapy Trials
par: Yingjie Qiu, et autres
Publié: (2026)

A Bayesian Treatment Selection Design for Phase II Randomised Cancer Clinical Trials
par: Moka Komaki, et autres
Publié: (2026)

DOD ‐ SSR : An Adaptive Seamless Phase II / III Design With Dose Optimization Decision and Sample Size Re‐estimation
par: Meizi Liu, et autres
Publié: (2025)

Using Win Odds to Improve Commit‐to‐Phase‐3 Decision‐Making in Oncology
par: Benjamin F. Hartley, et autres
Publié: (2025)

Cumulative Logit Ordinal Regression With Proportional Odds Under Nonignorable Missing Responses—Application to Phase III Trial
par: Arnab Kumar Maity, et autres
Publié: (2025)

Preference‐Informed Cluster Randomized Design for Pragmatic Clinical Trials
par: Yuwei Cheng, et autres
Publié: (2026)

A Partially Randomized Patient Preference, Sequential, Multiple‐Assignment, Randomized Trial Design Analyzed via Weighted and Replicated Frequentist and Bayesian Methods
par: Marianthie Wank, et autres
Publié: (2024)

The Win Ratio Approach in Bayesian Monitoring for Two‐Arm Phase II Clinical Trial Designs With Multiple Time‐To‐Event Endpoints
par: Xinran Huang, et autres
Publié: (2024)

A Comparison of Statistical Methods for Time‐To‐Event Analyses in Randomized Controlled Trials Under Non‐Proportional Hazards
par: Florian Klinglmüller, et autres
Publié: (2025)

Adaptive Biomarker‐Based Design for Early Phase Clinical Trials
par: Alessandra Serra, et autres
Publié: (2025)

Designing Stepped Wedge Cluster Randomized Trials With a Baseline Measurement of the Outcome
par: Kendra Davis‐Plourde, et autres
Publié: (2025)

What Is Fair? Defining Fairness in Machine Learning for Health
par: Jianhui Gao, et autres
Publié: (2025)

Unlocking Cognitive Analysis Potential in Alzheimer's Disease Clinical Trials: Investigating Hierarchical Linear Models for Analyzing Novel Measurement Burst Design Data
par: Guoqiao Wang, et autres
Publié: (2024)

Confidence Intervals for Adaptive Trial Designs II : Case Study and Practical Guidance
par: David S. Robertson, et autres
Publié: (2025)

BAR12 : Bayesian Autoregressive Phase 1‐2 Design for Cell Therapy Trials With Manufacturing Changes
par: Cheng‐Han Yang, et autres
Publié: (2026)

Design and Analysis of Group Sequential Trials for Repeated Measurements When Pipeline Data Occurs: A Tutorial
par: Corine Baayen, et autres
Publié: (2025)

Active‐Controlled Trial Design for HIV Prevention Trials With a Counterfactual Placebo
par: Fei Gao, et autres
Publié: (2025)

Exact Randomized Two‐Stage Phase 2 Clinical Trial Designs for Two Binary Co‐Primary Endpoints
par: Hyejung Jung, et autres
Publié: (2026)

Fiducial Confidence Intervals for Agreement Measures Among Raters Under a Generalized Linear Mixed Effects Model
par: Soumya Sahu, et autres
Publié: (2026)

Patient‐Centric Pragmatic Clinical Trials: Opening the DOOR
par: Scott R. Evans, et autres
Publié: (2026)

Negative Control Outcome Adjustment in Early‐Phase Randomized Trials: Estimating Vaccine Effects on Immune Responses in HIV Exposed Uninfected Infants
par: Ethan Ashby, et autres
Publié: (2025)

Estimating Risk Factors for Pathogenic Dose Accrual From Longitudinal Data
par: Daniel K. Sewell, et autres
Publié: (2025)

Survival Analysis Under the Aalen's Additive Hazards Model With Covariate Measurement Error: Application to Causal Mediation Analysis
par: Xialing Wen, et autres
Publié: (2025)

A Bayesian Dynamic Model‐Based Adaptive Design for Oncology Dose Optimization in Phase I/II Clinical Trials
par: Yingjie Qiu, et autres
Publié: (2024)

On Anticipation Effect in Stepped Wedge Cluster Randomized Trials
par: Hao Wang, et autres
Publié: (2026)

Specification of Estimands for Complex Disease Processes Using Multistate Models and Utility Functions
par: Alexandra Bühler, et autres
Publié: (2025)

Futility Monitoring in Clinical Trials
par: Ana M. Ortega‐Villa, et autres
Publié: (2025)

Dual‐agent dose‐finding in Phase I clinical trial—An extension of rapid enrollment design
par: Yunfei Wang
Publié: (2024)

Towards Efficient Time‐to‐Event Dose‐Escalation Guidance of Multi‐Cycle Cancer Therapies
par: Lukas A. Widmer, et autres
Publié: (2025)